Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Pulmonary Arterial Hypertension Clear all
Terminated Phase 2 Interventional Results available

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

NCT04791514
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 14, 2026, 1:07 AM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 14, 2026, 1:07 AM EDT
Terminated No phase listed Observational

[18F]FES PET/CT in PAH

NCT02899533
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
[18F] FES
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

NCT00705133
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Treprostinil
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 14, 2026, 1:07 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 14, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

NCT02939599
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 14, 2026, 1:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients

NCT04756076
View directory record Official record
Conditions
Pulmonary Hypertension, Metal Poison
Interventions
Metal level measurements
Diagnostic Test
Lead sponsor
Jiapeng Huang
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 14, 2026, 1:07 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neuromodulation in Patients With Pulmonary Arterial Hypertension

NCT06802380
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Low-level tragus stimulation, Sham stimulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 14, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

NCT07318597
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
REGN13335, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
RVT-1201, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers

NCT00814645
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

NCT01342952
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 14, 2026, 1:07 AM EDT
Recruiting Phase 1 Interventional

A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

NCT06481852
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Results available

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

NCT02587325
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

NCT00373360
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 14, 2026, 1:07 AM EDT
Active, not recruiting Not applicable Interventional

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

NCT06477640
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Exercise, Standard of Care
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 14, 2026, 1:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in the Evaluation of Chronic Lung Disease

NCT00926523
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
Interventions
Blood Gas, Pulmonary Exercise Test, Spirometry, Breath Condensate Collector
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2011 · Synced Oct 14, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Ambrisentan in Children 8-18yrs

NCT01332331
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Ambrisentan - low dose, Ambrisentan - high dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
8 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Ascending Dose in Japanese Patients Bridging Study

NCT05065359
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 14, 2026, 1:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Coenzyme Q-10 and Pulmonary Arterial Hypertension

NCT01148836
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Coenzyme Q-10 in Pulmonary Hypertension subjects, Coenzyme Q-10 in Normal Control subjects
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 14, 2026, 1:07 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

NCT04062565
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Injectable Product, Riociguat Pill
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 14, 2026, 1:07 AM EDT